Merck, Inc.
A Study of Suvorexant (MK-4305) for the Treatment of Insomnia in Participants With Opioid Use Disorder (MK-4305-098)
- First Posted Date
- 2024-10-24
- Last Posted Date
- 2025-01-31
- Lead Sponsor
- Merck Sharp & Dohme LLC
- Target Recruit Count
- 300
- Registration Number
- NCT06655883
A Study to Evaluate Safety, Tolerability, and Immunogenicity of V350A and V350B in Healthy Participants (V350-001).
- Conditions
- Healthy
- Interventions
- First Posted Date
- 2024-10-23
- Last Posted Date
- 2025-04-20
- Lead Sponsor
- Merck Sharp & Dohme LLC
- Target Recruit Count
- 200
- Registration Number
- NCT06655324
- Locations
- 🇺🇸
California Clinical Trials Medical Group managed by PAREXEL ( Site 0011), Glendale, California, United States
🇺🇸QPS-MRA, LLC ( Site 0012), Miami, Florida, United States
🇺🇸Alliance for Multispecialty Research, LLC ( Site 0008), Kansas City, Missouri, United States
A Study of Enlicitide Chloride (MK-0616) in Healthy Participants and Participants Taking Statins (MK-0616-012)
- Conditions
- HealthyHypercholesterolemia
- Interventions
- Other: Placebo
- First Posted Date
- 2024-10-23
- Last Posted Date
- 2024-10-23
- Lead Sponsor
- Merck Sharp & Dohme LLC
- Target Recruit Count
- 56
- Registration Number
- NCT06655311
- Locations
- 🇺🇸
Altasciences Clinical Kansas, Inc. (Site 0002), Overland Park, Kansas, United States
Extension Study of Long-term Safety and Efficacy of Tulisokibart in Participants With Crohn's Disease or Ulcerative Colitis (MK-7240-011)
- Conditions
- Crohn DiseaseColitis, Ulcerative
- Interventions
- Drug: Placebo to tulisokibart
- First Posted Date
- 2024-10-21
- Last Posted Date
- 2025-05-13
- Lead Sponsor
- Merck Sharp & Dohme LLC
- Target Recruit Count
- 1380
- Registration Number
- NCT06651281
- Locations
- 🇵🇱
Przychodnia Futuremeds Wroclaw ( Site 2211), Wroclaw, Dolnoslaskie, Poland
🇵🇱Centrum Diagnostyczno - Lecznicze Barska sp. z o.o. ( Site 2208), Wloclawek, Kujawsko-pomorskie, Poland
🇵🇱Bonifraterskie Centrum Medyczne ( Site 2207), Lodz, Lodzkie, Poland
MK-6194 Site of Injection Study in Healthy Adult Participants (MK-6194-013)
- First Posted Date
- 2024-10-21
- Last Posted Date
- 2024-10-21
- Lead Sponsor
- Merck Sharp & Dohme LLC
- Target Recruit Count
- 16
- Registration Number
- NCT06649877
- Locations
- 🇺🇸
QPS-MRA, LLC-Early Phase (Site 0001), South Miami, Florida, United States
A Clinical Study of MK-1708 in Healthy Elderly Participants (MK-1708-005)
- First Posted Date
- 2024-10-18
- Last Posted Date
- 2025-05-15
- Lead Sponsor
- Merck Sharp & Dohme LLC
- Target Recruit Count
- 16
- Registration Number
- NCT06647628
- Locations
- 🇺🇸
Velocity Clinical Research, Hallandale Beach ( Site 0001), Hallandale Beach, Florida, United States
A Study of MK-2225 in Healthy Participants (MK-2225-003)
- First Posted Date
- 2024-10-16
- Last Posted Date
- 2025-04-25
- Lead Sponsor
- Merck Sharp & Dohme LLC
- Target Recruit Count
- 32
- Registration Number
- NCT06643390
- Locations
- 🇺🇸
Clinical Pharmacology of Miami (Site 0002), Miami, Florida, United States
🇺🇸Bio-Kinetic Clinical Applications, LLC dba QPS-MO (Site 0004), Springfield, Missouri, United States
A Clinical Study of Enlicitide in Participants With Severe Renal Impairment (MK-0616-032)
- First Posted Date
- 2024-10-16
- Last Posted Date
- 2025-03-20
- Lead Sponsor
- Merck Sharp & Dohme LLC
- Target Recruit Count
- 24
- Registration Number
- NCT06643377
- Locations
- 🇺🇸
Nature Coast Clinical Research - Inverness ( Site 0002), Inverness, Florida, United States
🇺🇸Genesis Clinical Research, LLC ( Site 0001), Tampa, Florida, United States
🇺🇸Velocity Clinical Research, Hallandale Beach ( Site 0006), Hallandale Beach, Florida, United States
A Clinical Study of Sacituzumab Tirumotecan (MK-2870) in Patients With Bladder Cancer (MK-2870-027)
- Conditions
- Non-Muscle Invasive Bladder Cancer
- Interventions
- First Posted Date
- 2024-10-15
- Last Posted Date
- 2025-05-25
- Lead Sponsor
- Merck Sharp & Dohme LLC
- Target Recruit Count
- 32
- Registration Number
- NCT06637423
- Locations
- 🇳🇱
Erasmus Medisch Centrum ( Site 0032), Rotterdam, Zuid-Holland, Netherlands
🇺🇸Michael G Oefelein Clinical Trials ( Site 0053), Bakersfield, California, United States
🇺🇸Northwestern University ( Site 0051), Chicago, Illinois, United States
A Drug-Drug Interaction Study of Carbamazepine and Opevesostat (MK-5684) in Healthy Adult Male Participants (MK-5684-012)
- Conditions
- Healthy
- Interventions
- First Posted Date
- 2024-10-09
- Last Posted Date
- 2025-05-25
- Lead Sponsor
- Merck Sharp & Dohme LLC
- Target Recruit Count
- 14
- Registration Number
- NCT06633419
- Locations
- 🇺🇸
Celerion ( Site 0001), Tempe, Arizona, United States